<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling is associated with <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) kinase, a downstream effector of PI3K/Akt signaling, regulates <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>, indicating that mTOR inhibition may have therapeutic potential </plain></SENT>
<SENT sid="2" pm="."><plain>Notwithstanding, many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, demonstrate resistance to the antitumorigenic effects of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we show that inhibition of mTORC1 with <z:chebi fb="0" ids="9168">rapamycin</z:chebi> leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to <z:chebi fb="0" ids="9168">rapamycin</z:chebi> resistance </plain></SENT>
<SENT sid="4" pm="."><plain>Combination with the multikinase inhibitor, <z:chebi fb="0" ids="50924">sorafenib</z:chebi>, abrogates <z:chebi fb="0" ids="9168">rapamycin</z:chebi>-induced activation of PI3K/Akt and Ras-MAPK signaling pathways </plain></SENT>
<SENT sid="5" pm="."><plain>Combination of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> with <z:chebi fb="0" ids="50924">sorafenib</z:chebi> synergistically inhibits proliferation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either <z:chebi fb="0" ids="9168">rapamycin</z:chebi> or <z:chebi fb="0" ids="50924">sorafenib</z:chebi> monotherapy, but highly sensitive to combination treatment with <z:chebi fb="0" ids="9168">rapamycin</z:chebi> and <z:chebi fb="0" ids="50924">sorafenib</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Combination with <z:chebi fb="0" ids="50924">sorafenib</z:chebi> enhances therapeutic efficacy of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> on induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and inhibition of cell-cycle progression, migration and invasion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>We demonstrate efficacy and safety of concomitant treatment with <z:chebi fb="0" ids="9168">rapamycin</z:chebi> and <z:chebi fb="0" ids="50924">sorafenib</z:chebi> at inhibiting growth of xenografts from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells with coexistent mutations in KRAS and PIK3CA </plain></SENT>
<SENT sid="9" pm="."><plain>The efficacy and tolerability of combined treatment with <z:chebi fb="0" ids="9168">rapamycin</z:chebi> and <z:chebi fb="0" ids="50924">sorafenib</z:chebi> provides rationale for use in treating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, particularly those with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> harboring coexistent KRAS and PIK3CA mutations </plain></SENT>
</text></document>